Bilateral non-arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C [26]

Eye

Volumn 21, Issue 6, 2007, Pages 877-878

  Chan, J W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; ISCHEMIC OPTIC NEUROPATHY; LETTER; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SLIT LAMP; VISUAL IMPAIRMENT;

EID: 34250323886     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702749     Document Type: Letter

References (6)

1. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(Suppl 1): S237-S244.
2. Morrissey SP, Borruat FX, Miller DH, Moseley IF, Sweeney MG, Govan GG. Bilateral simultaneous optic neuropathy in adults: Clinical, imaging, serological, and genetic studies. J Neurol Neurosurg Psychiatry 1995; 58: 70-74.
3. Kirchhoff A, Kirchhoff U, Lafrenz M, Guthoff R. Bilateral AION after the combined herapy of hepatitis C with PEG-interferon alpha2B and ribavirin. Klin Monatsbl Augenheilkd 2004; 221: 791-793.
4. Willson RA. Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection. J Clin Gastroenterol 2004; 38: 717-722.
5. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
6. Lohmann CP, Gabler B, Kroher G, Spiegel D, Linde HJ, Reischl U. Severe loss of vision during adjuvant interferon alfa 2b treatment for malignant melanoma. Lancet 1999; 353: 1326.